Last reviewed · How we verify
Ad26.ZEBOV, MVA-BN-Filo
Ad26.ZEBOV, MVA-BN-Filo is a Vaccine Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 2 development for Ebola. Also known as: VAC52150.
Replicon-based vaccine targeting Zaire ebolavirus
Replicon-based vaccine targeting Zaire ebolavirus Used for Ebola.
At a glance
| Generic name | Ad26.ZEBOV, MVA-BN-Filo |
|---|---|
| Also known as | VAC52150 |
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Vaccine |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
The Ad26.ZEBOV vaccine is a recombinant adenovirus vector-based vaccine that expresses the Zaire ebolavirus glycoprotein. The MVA-BN-Filo vaccine is a modified vaccinia virus Ankara-based vaccine that expresses the filovirus glycoprotein.
Approved indications
- Ebola
Common side effects
Key clinical trials
- A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers (PHASE1)
- A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants (PHASE3)
- A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants (PHASE3)
- A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants (PHASE2)
- A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants (PHASE3)
- Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study (PHASE2)
- Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo (PHASE2)
- A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad26.ZEBOV, MVA-BN-Filo CI brief — competitive landscape report
- Ad26.ZEBOV, MVA-BN-Filo updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI
Frequently asked questions about Ad26.ZEBOV, MVA-BN-Filo
What is Ad26.ZEBOV, MVA-BN-Filo?
How does Ad26.ZEBOV, MVA-BN-Filo work?
What is Ad26.ZEBOV, MVA-BN-Filo used for?
Who makes Ad26.ZEBOV, MVA-BN-Filo?
Is Ad26.ZEBOV, MVA-BN-Filo also known as anything else?
What drug class is Ad26.ZEBOV, MVA-BN-Filo in?
What development phase is Ad26.ZEBOV, MVA-BN-Filo in?
Related
- Drug class: All Vaccine drugs
- Manufacturer: London School of Hygiene and Tropical Medicine — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Ebola
- Also known as: VAC52150
- Compare: Ad26.ZEBOV, MVA-BN-Filo vs similar drugs
- Pricing: Ad26.ZEBOV, MVA-BN-Filo cost, discount & access